New Delhi: The India Council of Medical Research (ICMR) on Wednesday (November 18) said that indiscriminate use of Convalescent Plasma Therapy (CPT) should be avoided as it does not reduce mortality in COVID-19 patients. Issuing Standard Operating Procedure (SoP), the apex medical research body advised states to desist from indiscriminate use of plasma therapy.
The ICMR‘s new advisory said, “ICMR conducted an open-label phase II multicentre randomised controlled trial in India across 39 public and private hospitals on use of convalescent plasma in the management of cases with moderate COVID-19 disease (PLACID Trial). It was concluded that CPT did not lead to a reduction in progression to severe COVID19 or all cause mortality in the group that received CPT as compared to the group that did not receive CPT.”
It further said, “PLACID is the world`s largest pragmatic trial on CPT conducted in 464 moderately ill laboratory-confirmed COVID-19 affected adults in real-world setting wherein no benefit of use of CPT could be established.” it said.
The ICMR also mentioned that similar studies conducted in China and the Netherlands have also documented no significant benefit of CPT in improving the clinical outcomes of hospitalised COVID-19 patients, hence indiscriminate use of CPT is not advisable.
“It is speculated that convalescent plasma having a low concentration of specific antibody against SARS-CoV-2 may be less beneficial for treating COVID-19 patients as compared to plasma with a high concentration of such antibodies,” said the guidance note.
The note further said, “This ICMR advisory, therefore, embraces the principle that a potential donor for convalescent plasma should have sufficient concentration of antibody working against COVID19,” adding that a potential donor of CPT can be a male and female–who have never been pregnant can only donate plasma.
Accordingly, the donor should be in the age group of 18-65 years who after 14 days of symptom resolution — testing negative for COVID-19 is not necessary, can donate plasma.
For the potential recipient, the ICMR, however, said that donor can be in the early stage of COVID-19 and the therapy should be administered between 3-7 days from onset of symptoms, but no later than 10 days. There should be no IgG antibody against COVID-19 by appropriate test and informed consent has to be taken.
The ICMR note further highlighted that presence of antibodies against COVID-19 in a potential recipient makes transfusing convalescent plasma a futile intervention, adding “CPT, therefore, should only be used, as advised by ICMR NTF, for management of COVID-19 when specific criteria are fulfilled.”
The ICMR advisory has been issued in the wake of Union Home Minister Amit Shah’s meeting to assess the COVID-19 situation in Delhi, wherein it was discussed to issue SoP for plasma therapy and plasma administration for treatment of coronavirus patients immediately.
(With Agency Inputs)